Answers are grounded in this paper and cite their sources.
Review highlights immunotherapy's evolution in treating head and neck squamous cell carcinoma, suggesting improved outcomes and novel strategies.
Head and neck squamous cell carcinoma (HNSCC) ranks as the seventh most common cancer globally, with etiological subtypes—carcinogen-driven (human papillomavirus [HPV-negative]) and HPV-driven—shaping tumor immunogenicity and treatment responses. This review highlights immunotherapy’s evolution, focusing on PD-1/PD-L1 blockade. HPV-positive tumors feature a “hot” microenvironment with dense tumor-infiltrating lymphocytes (TILs) and PD-L1 upregulation, yielding better immune checkpoint inhibitor (ICI) outcomes. In contrast, HPV-negative cases exhibit a “cold,” immunosuppressive profile with inferior ICI responses. Landmark trials like KEYNOTE-048 and CheckMate 141 established pembrolizumab and nivolumab as standards for recurrent/metastatic HNSCC, improving median OS (overall survival) by 2 to 4 months over the EXTREME regimen (cetuximab plus platinum-based chemotherapy), especially in patients with PD-L1 Combined Positive Score (CPS) ⩾ 1. Combination strategies enhance efficacy through multiple mechanisms: chemotherapy induces immunogenic cell death, radiotherapy elicits abscopal effects, and cetuximab provides additional antitumor activity. In locally advanced disease, the KEYNOTE-689 trial demonstrated superior event-free survival with perioperative pembrolizumab versus placebo (59.7 vs 29.6 months), supporting treatment de-escalation strategies. Management of immune-related adverse events follows established NCCN/SITC guidelines. Emerging therapies, including anti-LAG-3/TIM-3 and oncolytic viruses, target resistance. Future efforts emphasize multiomic biomarkers and equitable access to optimize outcomes in this heterogeneous malignancy.
No takes yet. Share an insight, caveat, or question.
Fei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: